By Sumeet Chatterjee and Ben Hirschler MUMBAI/LONDON (Reuters) - Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said. An Indian government committee is reviewing patented drugs of foreign firms to see if so-called compulsory licenses, which in effect break exclusivity rights, can be issued for some of them to bring down costs, two senior government officials told Reuters. The drugs that are part of the review process are used for treating cancer, diabetes, hepatitis and HIV, said the sources, declining to give details. No timeline has been given for completion of the review process. Emerging markets, from South Africa to China and India, are battling to bring down healthcare costs and boost access to drugs to treat diseases such as cancer, HIV/AIDS and hepatitis. Western drugmakers, including Pfizer Inc, Novartis AG, Roche Holding AG and Sanofi SA, covet a bigger share of the fast-growing drugs market in India. But they have been frustrated by a series of decisions on patents and pricing, as part of New Delhi's push to increase access to life-saving treatments where only 15 percent of 1.2 billion people are covered by health insurance. India is currently on the U.S. government's Priority Watch List - countries whose practices on protecting intellectual property Washington believes should be monitored closely. The U.S. industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA) believes Washington should take a tougher line by downgrading it to a Priority Foreign Country, a classification for the worst offenders, which may trigger possible actions, sources said. "The multinational companies are exploring all options - from paring their investments in the country to forcing the U.S. to take some actions," said a source in New Delhi, who is directly involved in the situation. "Companies feel something should be done at the earliest to check the violations of their intellectual property in the country. They want government-to-government pressure to change things," he said. All the sources declined to be named due to sensitivity of the matter. A PhRMA representative declined to comment. If India gets relegated by the United States to Priority Foreign Country level, it will join Ukraine as the second country in that segment. Countries in the Priority Watch List include China, Indonesia, Pakistan, Russia, Thailand and Argentina. "PhRMA makes submissions to the U.S. government every year on trade issues but this year they really want to ratchet up the pressure on India," said one executive with a multinational drug company. PhRMA is currently drawing up a submission to the U.S. government ahead of a Friday deadline for filing concerns about countries to be included in the so-called Special 301 Report, which is prepared annually by the Office of the United States Trade Representative. POLITICALLY SENSITIVE Making medicines cheaper is a politically sensitive issue in India where many patented drugs are too costly for most people, 40 percent of whom earn less than $1.25 a day, and where patented drugs account for under 10 percent of total drug sales. Picking a fight with an emerging economy like India, where millions of people cannot afford basic healthcare, will not be easy and without risks. The industry has recently run into fierce controversy in South Africa for taking on Pretoria over its plans to overhaul patent laws to favor cheaper generic drugs, leading some executives to urge a softer approach. "I don't believe there is any need for any kind of more assertive stance. This is a situation where constructive engagement is the way forward," GlaxoSmithKline Plc Chief Executive Andrew Witty told Reuters. With sales of patented drugs in Western countries slowing, emerging markets are a vital growth driver for companies. India, however, has so far failed to be much of a money-spinner for the world's top pharmaceutical companies. India's $14 billion-a-year drugs market - driven these days by chronic diseases, such as diabetes, as well as infections - is expected to be worth $22-32 billion by 2017, which would rank it as the 11th largest globally, according to IMS Health. "Any obstruction or action by the U.S. government can have a very adverse impact on the trade relations between the two countries," said D.H. Pai Panandiker, president of New Delhi-based RPG Foundation, an economic think-tank. "So, both sides will be cautious, but to protect their own interests they won't hesitate to take actions under the WTO (World Trade Organisation) provisions." In 2012, India issued its first ever compulsory license to domestic drugmaker Natco Pharma Ltd on a kidney and liver cancer drug, Nexavar, patented by Germany's Bayer AG, in a move that it had said endangered pharmaceutical research. AstraZeneca Plc last month decided to shut its R&D center in Bangalore citing broader global business strategy. Some analysts expect a few other global drugmakers to pare R&D spending given the uncertainty about the patent regime. "If the authorities are going haywire and looking to grant compulsory licenses lock, stock and barrel, in that event you will lose the credibility in India as a system," Meet Hariani, managing partner at Mumbai-based law firm Hariani & Co, said. "You are going to see much more litigation on this issue. People are going to be unwilling to introduce new drugs in the market," he said. "You can't expect to get a new drug at a price of an aspirin." (Additional reporting by Bill Berkrot in NEW YORK; Editing by Jeremy Laurence)
This says a lot, despite being only one word.
Justice Neil Gorsuch fumes that the Supreme Court 'failed' to 'honor this Nation's promises' as it rolled back tribal authority in Oklahoma
Gorsuch's dissenting opinion came as the nation's highest court handed more power to states over Native American lands.
GOP Rep. Ronny Jackson likely didn't receive the answers he was hoping for.
The Washington Examiner published the blistering editorial in the wake of bombshell testimony from the Jan. 6 committee hearings.
The famous public figure's meme centered on Donald Trump's apparent belief that he's entitled to grab whatever he wants.
- The Telegraph
The Prince of Wales enjoyed a “very emotional” first meeting with his granddaughter, Lilibet, a senior royal aide has revealed.
- Golf Channel
ZJ isn't too concerned about how LIV will affect his Ryder Cup squad. Others, however, are more anxious about their future status.
This isn't the first time he's been hospitalized.
- Rolling Stone
The former president lashed out at former Mark Meadows aide Cassidy Hutchinson, even describing her handwriting as "that of a Whacko"
- The New Voice of Ukraine
Odesa regional governor Serhiy Bratchuk said on Telegram on June 30 that according to unverified reports, a Russian landing craft hit a mine near Mariupol.
The Twitter account of the House Judiciary Committee Republicans had implied Cassidy Hutchinson's testimony before the Jan. 6 panel was "all hearsay."
- Good Morning America
Kevin Bacon has officially joined in on the TikTok "Footloose" challenge. The actor, who played Ren McCormack in the 1984 classic, shared a video of himself trying out the viral dance challenge with his wife, actress Kyra Sedgwick, on Tuesday. The challenge is set to the film's theme song of the same name by Kenny Loggins.
A Chinese father who reportedly tutored his son daily for a year went viral for bursting into tears after his son scored six out of 100 points on a math exam. The child’s parents from Zhengzhou, Henan Province, received his test score on June 23. Upon learning that their son had only received six points for his final math test, the father burst into tears, as seen in a video posted to Weibo by Qilu Evening News.
Kardashian was seen next to her husband as he was reportedly taken into Cedars-Sinai Medical Center on a stretcher Tuesday
Secret Service agents are prepared to testify that Trump did not lunge at them or try to take control of the car to reach the Capitol, reports say
Cassidy Hutchinson, a former aide to Mark Meadows, testified that Trump sought to go to the Capitol though he knew his supporters were armed.
- Rolling Stone
One of the witness tampering messages the Jan. 6 committee displayed on Tuesday was received by the former Mark Meadows aide, according to Punchbowl News
Salmonella bacteria have been discovered in the world's biggest chocolate plant, run by Swiss giant Barry Callebaut in the Belgian town of Wieze, the firm said Thursday.
Former White House chief of staff says Trump should be most worried about evidence the January 6 panel may have for obstruction of justice
Mick Mulvaney wrote an op-ed article saying Donald Trump could be the next politician to learn "it usually isn't the crime" but rather "the cover-up."
The comic/actor tore into one lawmaker over a basic U.S. civics fail.
- The Wrap
Liz Cheney Defends Cassidy Hutchinson After Reports of Secret Service Agents Disputing Her Testimony
"The committee's not going to stand by and watch her character be assassinated," Cheney said of the former White House aide